Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study. / Morville, Thomas; Dohlmann, Tine Lovso; Kuhlman, Anja Birk; Sahl, Ronni Eg; Kriegbaum, Margit; Larsen, Steen; Dela, Flemming; Helge, Jorn Wulff.
I: Medicine and Science in Sports and Exercise, Bind 51, Nr. 7, 2019, s. 1429-1437.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study
AU - Morville, Thomas
AU - Dohlmann, Tine Lovso
AU - Kuhlman, Anja Birk
AU - Sahl, Ronni Eg
AU - Kriegbaum, Margit
AU - Larsen, Steen
AU - Dela, Flemming
AU - Helge, Jorn Wulff
PY - 2019
Y1 - 2019
N2 - Introduction Statins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength. Methods A population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 +/- 1 yr) or without myalgia (NM; n = 37; 63 +/- 1 yr) as well as a control group not taking statins (C; n = 20; 60 +/- 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests. Results The response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); M, 27 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); NM, 28 +/- 1 mL O-2 center dot min(-1)center dot kg(-1)) or maximal fat oxidation (C, 247 +/- 26 mg center dot min(-1); M, 295 +/- 24 mg center dot min(-1); NM, 279 +/- 17 mg center dot min(-1)). Measurements of strength were similar in all three groups including rate of force development (C, 795 +/- 56 N center dot m center dot s(-1); M, 930 +/- 93 N center dot m center dot s(-1); NM, 971 +/- 57 N center dot m center dot s(-1)) and leg extension power (C: 2.6 +/- 0.2; M: 2.3 +/- 0.1; NM: 2.4 +/- 0.1 W center dot kg(-1)). All results are mean +/- SEM. Conclusion Statin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.
AB - Introduction Statins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength. Methods A population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 +/- 1 yr) or without myalgia (NM; n = 37; 63 +/- 1 yr) as well as a control group not taking statins (C; n = 20; 60 +/- 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests. Results The response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); M, 27 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); NM, 28 +/- 1 mL O-2 center dot min(-1)center dot kg(-1)) or maximal fat oxidation (C, 247 +/- 26 mg center dot min(-1); M, 295 +/- 24 mg center dot min(-1); NM, 279 +/- 17 mg center dot min(-1)). Measurements of strength were similar in all three groups including rate of force development (C, 795 +/- 56 N center dot m center dot s(-1); M, 930 +/- 93 N center dot m center dot s(-1); NM, 971 +/- 57 N center dot m center dot s(-1)) and leg extension power (C: 2.6 +/- 0.2; M: 2.3 +/- 0.1; NM: 2.4 +/- 0.1 W center dot kg(-1)). All results are mean +/- SEM. Conclusion Statin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.
KW - STATINS
KW - CHOLESTEROL
KW - AEROBIC CAPACITY
KW - STRENGTH
KW - MYALGIA
U2 - 10.1249/MSS.0000000000001920
DO - 10.1249/MSS.0000000000001920
M3 - Journal article
C2 - 31210648
VL - 51
SP - 1429
EP - 1437
JO - Medicine and Science in Sports and Exercise
JF - Medicine and Science in Sports and Exercise
SN - 0195-9131
IS - 7
ER -
ID: 223507154